OTCMKTS:SZLSF

StageZero Life Sciences (SZLSF) Stock Price, News & Analysis

$0.04
+0.01 (+33.33%)
(As of 04/24/2024 ET)
Today's Range
$0.03
$0.04
50-Day Range
$0.03
$0.04
52-Week Range
$0.03
$0.06
Volume
15,640 shs
Average Volume
71,021 shs
Market Capitalization
$4.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SZLSF stock logo

About StageZero Life Sciences Stock (OTCMKTS:SZLSF)

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.

SZLSF Stock Price History

SZLSF Stock News Headlines

He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Dually-Listed Healthcare Stock Rallies On Q1 Results
The A.I. story nobody is telling you (Read ASAP)
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
StageZero Life Sciences CFO resigns
StageZero Life Sciences Launches AVRT(TM) in the UK
See More Headlines
Receive SZLSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
OTCMKTS:SZLSF
Employees
40
Year Founded
N/A

Profitability

Net Income
$-11,410,000.00
Net Margins
-418.64%
Pretax Margin
-418.63%

Debt

Sales & Book Value

Annual Sales
$3.80 million
Book Value
($0.07) per share

Miscellaneous

Free Float
120,395,000
Market Cap
$4.94 million
Optionable
Not Optionable
Beta
0.61
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. James R. Howard-Tripp
    Executive Chairman & CEO
  • Dr. Choong-Chin Liew Ph.D.
    Co-Founder
  • Mr. Warren Whitehead C.M.A. (Age 72)
    CPA, Chief Accountant

SZLSF Stock Analysis - Frequently Asked Questions

How have SZLSF shares performed in 2024?

StageZero Life Sciences' stock was trading at $0.0294 at the start of the year. Since then, SZLSF stock has increased by 36.1% and is now trading at $0.04.
View the best growth stocks for 2024 here
.

How do I buy shares of StageZero Life Sciences?

Shares of SZLSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:SZLSF) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners